MADRIGAL PHARMACEUTICALS INC
MDGLNASDAQ🏆 #674 by market capEarnings Nov 2 · PreUS Equity
$535.27▲ $20.71 (+3.87%)
Market closed · at close1h—
24h▲ 3.9%
7d—
14d—
30d—
1y—
🏦Market Cap
$12.34B
Mid Cap
📈Revenue Growth (YoY)
+149.0%
High Growth
📊Gross Margin
91.5%
High
💵FCF Margin
7.4%
Moderate
⚖️P/S Ratio
9.3x
Elevated
Otter Score
50
Weak
📊
Analyst Ratings
Price
$535.27
Total
23
Raised
2
Lowered
1
Avg PT
$677.00
H / L
$962 / $542
| Institution | Action | Rating | Date |
|---|---|---|---|
Canaccord Genuity | Reiterated | Buy | 2026-07-29 |
B of A Securities | Reiterated | Neutral | 2026-06-11 |
Truist Securities | Reiterated | Buy | 2026-05-13 |
Evercore ISI Group | Reiterated | Outperform | 2026-05-07 |
HC Wainwright & Co. | Reiterated | Buy | 2026-05-06 |
Citizens | Reiterated | Market Outperform | 2026-01-20 |
Piper Sandler | Reiterated | Overweight | 2025-12-19 |
B. Riley Securities | Reiterated | Buy | 2025-12-11 |
Oppenheimer | Reiterated | Outperform | 2025-11-20 |
Cantor Fitzgerald | Upgraded | Neutral → Overweight | 2025-11-05 |
TD Cowen | Reiterated | Buy | 2025-08-26 |
JMP Securities | Reiterated | Market Outperform | 2025-08-20 |
UBS | Reiterated | Buy | 2025-08-12 |
Citigroup | Reiterated | Buy | 2025-02-27 |
SVB Leerink | Reiterated | Outperform | 2022-12-20 |
Goldman Sachs | Reiterated | Buy | 2022-12-20 |
Chardan Capital | Reiterated | Buy | 2021-02-26 |
BMO Capital | Reiterated | Market Perform | 2020-11-06 |
B. Riley FBR | Reiterated | Buy | 2020-05-22 |
Citi | Reiterated | Buy | 2019-12-02 |
B. Riley | Upgraded | Neutral → Buy | 2019-06-10 |
Raymond James | Downgraded | Market Perform → Underperform | 2018-11-19 |
H.C. Wainwright | Reiterated | Buy | 2018-06-01 |
One row per institution, most recent rating